Abnormalities in micturition: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 82: Line 82:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Contact dermatitis]]
| style="background: #DCDCDC; text-align: center;" |[[Contact dermatitis]]
Line 101: Line 101:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
! rowspan="7" style="background: #DCDCDC; text-align: center;" |[[Infectious disease|Infectious diseases]]
! rowspan="7" style="background: #DCDCDC; text-align: center;" |[[Infectious disease|Infectious diseases]]
Line 121: Line 121:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Urethritis]]
| style="background: #DCDCDC; text-align: center;" |[[Urethritis]]
Line 140: Line 140:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Pyelonephritis]]
| style="background: #DCDCDC; text-align: center;" |[[Pyelonephritis]]
Line 159: Line 159:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Vulvovaginitis]]
| style="background: #DCDCDC; text-align: center;" |[[Vulvovaginitis]]
Line 178: Line 178:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Cervicitis]]
| style="background: #DCDCDC; text-align: center;" |[[Cervicitis]]
Line 197: Line 197:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Prostatitis]]  
| style="background: #DCDCDC; text-align: center;" |[[Prostatitis]]  
Line 216: Line 216:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Epididymoorchitis]]
| style="background: #DCDCDC; text-align: center;" |[[Epididymoorchitis]]
Line 235: Line 235:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
! rowspan="11" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Non-inflammatory
! rowspan="11" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Non-inflammatory
Line 256: Line 256:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Benign prostatic hyperplasia|Benign prostatic hyperplasia (BPH)]]
| style="background: #DCDCDC; text-align: center;" |[[Benign prostatic hyperplasia|Benign prostatic hyperplasia (BPH)]]
Line 275: Line 275:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Drug]]
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Drug]]
Line 295: Line 295:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Cyclophosphamide]]
| style="background: #DCDCDC; text-align: center;" |[[Cyclophosphamide]]
Line 314: Line 314:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Endocrine disorders]]
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Endocrine disorders]]
Line 334: Line 334:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Endometriosis]]
| style="background: #DCDCDC; text-align: center;" |[[Endometriosis]]
Line 353: Line 353:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Malignancy]]
! rowspan="2" style="background: #DCDCDC; text-align: center;" |[[Malignancy]]
Line 373: Line 373:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Vulvovaginal disorders|Vulvovaginal cancer]]
| style="background: #DCDCDC; text-align: center;" |[[Vulvovaginal disorders|Vulvovaginal cancer]]
Line 392: Line 392:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
! rowspan="3" style="background: #DCDCDC; text-align: center;" |[[Iatrogenic]]
! rowspan="3" style="background: #DCDCDC; text-align: center;" |[[Iatrogenic]]
Line 412: Line 412:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Pelvic]] [[irradiation]]
| style="background: #DCDCDC; text-align: center;" |[[Pelvic]] [[irradiation]]
Line 431: Line 431:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
| style="background: #DCDCDC; text-align: center;" |[[Trauma]]
| style="background: #DCDCDC; text-align: center;" |[[Trauma]]
Line 450: Line 450:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|}
|}


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Revision as of 17:22, 28 June 2018

Micturation Abnormalities Microchapters

Overview

Causes

Differential Diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Overview

Classification

Causes

Abnormalities of Micturation Differential Diagnosis

Differentiating the diseases that can cause abnormality in micturation:

Abbreviations: N= Normal, UTI= Urinary tract infection, CBC= Complete blood count, CT= Computed tomography, IBS= Irritable bowel syndrome,

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging
Fever Urinary symptoms Supra-pubic tenderness Skin lesions Other CBC Electrolytes Urinalysis Ultrasonography CT scan Other
Dysuria Frequency Dribbling Hesitancy Nocturia
Inflammatory Dermatological disorders Lichen sclerosus – + – – + – – Lichenified plaques – N N often shows UTI in women N N N Biopsy Associated with:[1]
Behcet's syndrome – + + – + + –
Contact dermatitis – - + - -
Infectious diseases Cystitis + +/- + - +
Urethritis + - + - +/-
Pyelonephritis + - + - +/-
Vulvovaginitis + + + - -
Cervicitis + +/- - - +
Prostatitis +/- + + + +
Epididymoorchitis +/- + +
Non-inflammatory Anatomic Urethral stricture
Benign prostatic hyperplasia (BPH) +
Drug Spermicides
Cyclophosphamide
Endocrine disorders Atrophic vaginitis
Endometriosis
Malignancy Bladder cancer
Vulvovaginal cancer
Iatrogenic Genitourinary instrumentation +
Pelvic irradiation
Trauma ±

References

  1. ↑ Ventolini G, Patel R, Vasquez R (2015). "Lichen sclerosus: a potpourri of misdiagnosed cases based on atypical clinical presentations". Int J Womens Health. 7: 511–5. doi:10.2147/IJWH.S82879. PMC 4431497. PMID 26056492.
Retrieved from "https://www.wikidoc.org/index.php?title=Abnormalities_in_micturition&oldid=1479972"